Ajanta Pharma is planning to enhance its presence across select geographies with high growth potential in Asia and Africa, as part of its growth plans. It intends to rely on its strengths to grow faster in countries where it has a presence with its range of branded generics.
The company's branded generics business accounted for 73 per cent of its revenues in FY 2023, with Indian, rest of Asia and Africa contributing 31 per cent, 26 per cent and 15 per cent, respectively. In order to achieve its targets, it has enhanced capital allocation to branded generics businesses across India, the rest of Asia and Africa.
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: